To further elucidate the molecular mechanisms by which PDGFRA mediates lenvatinib resistance in HCC cells, we conducted additional experiments to assess the expression of downstream targets of the PDGF/PDGFRA signaling pathway, including mTOR, AKT, MEK, and ERK. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.